WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Summary

A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

Timeline

Start

2022-12-06

Primary completion

2024-12-23

Completion

2025-02-05

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “announced initial safety and efficacy data from its ongoing Phase 1 clinical trial of WTX-330” werewolftx.com ↗

release “Preliminary clinical findings presented at SITC demonstrate WTX-330’s promising therapeutic potential as a monotherapy, exhibiting a favorable tolerability profile and inducing tumor shrinkage” werewolftx.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WTX-330	Protein / enzyme biologic	—	—

Indications